Global Strategic Investment Solutions LLC Reduces Stake in Catalent, Inc. (NYSE:CTLT)

Global Strategic Investment Solutions LLC cut its position in Catalent, Inc. (NYSE:CTLT) by 29.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,718 shares of the company’s stock after selling 2,000 shares during the quarter. Global Strategic Investment Solutions LLC’s holdings in Catalent were worth $286,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Gamco Investors INC. ET AL grew its stake in Catalent by 403.3% during the first quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after acquiring an additional 20,273 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Catalent by 2,792.9% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after acquiring an additional 498,540 shares during the last quarter. UniSuper Management Pty Ltd raised its stake in Catalent by 509.4% in the first quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock valued at $1,028,000 after purchasing an additional 15,217 shares in the last quarter. Swedbank AB bought a new stake in Catalent during the first quarter valued at approximately $1,659,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Catalent by 147.4% during the 1st quarter. SG Americas Securities LLC now owns 99,588 shares of the company’s stock worth $5,622,000 after acquiring an additional 59,339 shares during the last quarter.

Insider Activity

In related news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.31% of the company’s stock.

Catalent Stock Up 0.1 %

Shares of NYSE CTLT traded up $0.08 on Thursday, reaching $60.03. 301,274 shares of the company’s stock traded hands, compared to its average volume of 2,041,098. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The business’s 50 day simple moving average is $60.03 and its two-hundred day simple moving average is $58.03. Catalent, Inc. has a 12 month low of $32.38 and a 12 month high of $61.20. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -10.92, a price-to-earnings-growth ratio of 2.06 and a beta of 1.16.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the firm posted ($0.10) EPS. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. As a group, equities research analysts forecast that Catalent, Inc. will post 0.95 EPS for the current fiscal year.

Analysts Set New Price Targets

CTLT has been the subject of several analyst reports. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a report on Wednesday. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.